These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 22030001

  • 1. Reversible cardiomyopathy associated with sunitinib and sorafenib.
    Uraizee I, Cheng S, Moslehi J.
    N Engl J Med; 2011 Oct 27; 365(17):1649-50. PubMed ID: 22030001
    [No Abstract] [Full Text] [Related]

  • 2. Secondary erythrocytosis produced by the tyrosine kinase inhibitors sunitinib and sorafenib.
    Alexandrescu DT, McClure R, Farzanmehr H, Dasanu CA.
    J Clin Oncol; 2008 Aug 20; 26(24):4047-8. PubMed ID: 18711201
    [No Abstract] [Full Text] [Related]

  • 3. A preeclampsia-like syndrome characterized by reversible hypertension and proteinuria induced by the multitargeted kinase inhibitors sunitinib and sorafenib.
    Patel TV, Morgan JA, Demetri GD, George S, Maki RG, Quigley M, Humphreys BD.
    J Natl Cancer Inst; 2008 Feb 20; 100(4):282-4. PubMed ID: 18270341
    [No Abstract] [Full Text] [Related]

  • 4. [Cutaneous side effects of sorafenib and sunitinib].
    Autier J, Mateus C, Wechsler J, Spatz A, Robert C.
    Ann Dermatol Venereol; 2008 Feb 20; 135(2):148-53; quiz 147, 154. PubMed ID: 18342102
    [No Abstract] [Full Text] [Related]

  • 5. Risk of bleeding not increased by sorafenib or sunitinib.
    Minor DR.
    Lancet Oncol; 2010 Feb 20; 11(2):112-3; author reply 113. PubMed ID: 20152763
    [No Abstract] [Full Text] [Related]

  • 6. [New drugs; sunitinib and sorafenib].
    van Bronswijk H, Dubois EA, Osanto S, Cohen AF.
    Ned Tijdschr Geneeskd; 2007 Dec 29; 151(52):2888-90. PubMed ID: 18257434
    [Abstract] [Full Text] [Related]

  • 7. Kidney cancer: Does hypothyroidism predict clinical outcome?
    Rini B.
    Nat Rev Urol; 2011 Jan 29; 8(1):10-1. PubMed ID: 21116300
    [No Abstract] [Full Text] [Related]

  • 8. Sorafenib and sunitinib.
    Kim A, Balis FM, Widemann BC.
    Oncologist; 2009 Aug 29; 14(8):800-5. PubMed ID: 19648603
    [No Abstract] [Full Text] [Related]

  • 9. Is hypothyroidism a clinically relevant toxicity of tyrosine kinase inhibitors?
    Torino F, Corsello SM, Longo R, Barnabei A, Gasparini G.
    Thyroid; 2009 May 29; 19(5):539-40. PubMed ID: 19416001
    [No Abstract] [Full Text] [Related]

  • 10. [Role of VEGFR-TKIs in the treatment of renal cell carcinoma].
    Kondo T.
    Nihon Jinzo Gakkai Shi; 2012 May 29; 54(5):574-80. PubMed ID: 22991835
    [No Abstract] [Full Text] [Related]

  • 11. Thyroid dysfunction in patients treated with tyrosine kinase inhibitors, sunitinib, sorafenib and axitinib, for metastatic renal cell carcinoma.
    Daimon M, Kato T, Kaino W, Takase K, Karasawa S, Wada K, Kameda W, Susa S, Oizumi T, Tomita Y, Kato T.
    Jpn J Clin Oncol; 2012 Aug 29; 42(8):742-7. PubMed ID: 22628612
    [Abstract] [Full Text] [Related]

  • 12. Acute exacerbation of hemorrhagic rectocolitis during antiangiogenic therapy with sunitinib and sorafenib.
    Loriot Y, Boudou-Rouquette P, Billemont B, Ropert S, Goldwasser F.
    Ann Oncol; 2008 Nov 29; 19(11):1975. PubMed ID: 18723549
    [No Abstract] [Full Text] [Related]

  • 13. Effect of the tyrosine kinase inhibitors (sunitinib, sorafenib, dasatinib, and imatinib) on blood glucose levels in diabetic and nondiabetic patients in general clinical practice.
    Agostino NM, Chinchilli VM, Lynch CJ, Koszyk-Szewczyk A, Gingrich R, Sivik J, Drabick JJ.
    J Oncol Pharm Pract; 2011 Sep 29; 17(3):197-202. PubMed ID: 20685771
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target?
    Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM.
    Oncologist; 2010 Sep 29; 15(2):130-41. PubMed ID: 20139170
    [Abstract] [Full Text] [Related]

  • 17. Risk of arterial thrombosis not increased by sorafenib or sunitinib.
    Minor DR.
    J Clin Oncol; 2010 Oct 20; 28(30):e619; author reply e620. PubMed ID: 20733133
    [No Abstract] [Full Text] [Related]

  • 18. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials.
    Je Y, Schutz FA, Choueiri TK.
    Lancet Oncol; 2009 Oct 20; 10(10):967-74. PubMed ID: 19767240
    [Abstract] [Full Text] [Related]

  • 19. A case of acute haemolysis with 2 different multi target thyrosine kinase inhibitors in a patient with renal cancer.
    Berchem G, Dewilde S, Mahassen P.
    Bull Soc Sci Med Grand Duche Luxemb; 2009 Oct 20; (1):7-9. PubMed ID: 19514172
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.